Selenoprotein P as Biomarker of Selenium Status in Clinical Trials with Therapeutic Dosages of Selenite

Brodin, Ola; Hackler, Julian; Misra, Santosh; Wendt, Sebastian; Sun, Qian; Laaf, Elena; Stoppe, Christian; Björnstedt, Mikael; Schomburg, Lutz

doi:10.3390/nu12041067

Cited by 47 publications

(36 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When nutritional adequacy is being assessed, functional biomarkers quickly responsive to changes in diet, such as selenoproteins, are the biomarkers of choice to evaluate exposure to Se. In this regard, samples of plasma and serum Se, which are virtually equivalent with respect to Se-containing components, are especially useful to monitor Se status in supplementation studies [ 21 ], even at doses above the tolerable upper intake level [ 22 ]. Whole blood Se, on the other hand, has been proposed as a better indicator of intermediate to long term average exposure [ 21 ], with slower responses to recent changes in dietary intake [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

Selenium and impaired physical function in US and Spanish older adults

et al. 2021

View full text Add to dashboard Cite

Background Selenium (Se) is a trace element with a narrow safety margin. Objectives To evaluate the cross-sectional and longitudinal dose-response association between Se exposure and measures of impaired physical function and disability in older adults. Design NHANES 2011–2014 cross-sectional (US, n = 1733, age ≥60 years) and Seniors-ENRICA-2 2017–2019 cross-sectional and longitudinal (Spain, n = 2548 and 1741, respectively, age ≥65 years) data were analyzed. Whole blood and serum Se levels were measured using inductively coupled plasma-mass spectrometry. Lower-extremity performance was assessed with the Short Physical Performance Battery, and muscle weakness with a dynamometer. Incident mobility and agility limitations, and disability in instrumental activities of daily living (IADL) were ascertained with standardized questionnaires. Analyses were adjusted for relevant confounders, including physical activity. Results across studies were pooled using random-effects meta-analysis. Results Meta-analyzed odds ratios (95% confidence interval) per log2 increase in whole blood Se were 0.54 (0.32; 0.76) for weakness, 0.59 (0.34; 0.83) for impaired lower-extremity performance, 0.48 (0.31; 0.68) for mobility limitations, 0.71 (0.45; 0.97) for agility limitations, and 0.34 (0.12; 0.56) for disability in at least one IADL. Analyses for serum Se in NHANES showed similar results. Findings suggest the inverse association with grip strength is progressive below 140 μg/L (p-value for non-linear trend in the Seniors-ENRICA-2 study = 0.13), and above 140 μg/L (p-value for non-linear trend in NHANES = 0.11). In the Seniors-ENRICA-2 cohort, with a 2.2 year follow-up period, a doubling in baseline Se levels were associated with a lower incidence of weakness [odds ratio (95% confidence interval): 0.45 (0.22; 0.91)], impaired lower-extremity performance [0.63 (0.32; 1.23)], mobility [0.43 (0.21; 0.91)] and agility [0.38 (0.18; 0.78)] limitations. Discussion In US and Spanish older adults, Se concentrations were inversely associated with physical function limitations. Further studies are needed to elucidate underlying mechanisms.

show abstract

Section: Discussionmentioning

confidence: 99%

Selenium and impaired physical function in US and Spanish older adults

et al. 2021

View full text Add to dashboard Cite

show abstract

“…1 Functions of selenium in various organisms deficiency reduces the content of SelP [14]. It was found that after administration of Se, the concentration of SelP increases first, and only then does the concentration of other Sedependent proteins increase [15]. SelP is produced in hepatocytes [13].…”

Section: Selenoprotein-p (Selp)mentioning

confidence: 99%

A Comprehensive Review on Selenium and Its Effects on Human Health and Distribution in Middle Eastern Countries

Kieliszek

Bano

Zare

2021

Biol Trace Elem Res

View full text Add to dashboard Cite

Selenium (Se) is an important microelement with numerous positive effects on human health and diseases. It is important to specify that the status and consumption of Se are for a specific community as the levels of Se are extremely unpredictable between different populations and regions. Our existing paper was based on the impacts of Se on human health and disease along with data on the Se levels in Middle Eastern countries. Overall, the findings of this comprehensive review show that the consumption and levels of Se are inadequate in Middle Eastern nations. Such findings, together with the growing awareness of the importance of Se to general health, require further work primarily on creating an acceptable range of blood Se concentration or other measures to determine optimal Se consumption and, consequently, to guarantee adequate Se supplementation in populations at high risk of low Se intake.

show abstract

“…Several biomarkers for detecting Se deficiency and monitoring successful supplementation effects have been evaluated [ 8 ]. Among the different candidates, three parameters emerged as the most informative ones, i.e., enzymatic activity of the secreted glutathione peroxidase (GPx3) in serum or plasma, concentration of total serum or plasma Se, and the expression level of the circulating Se transporter selenoprotein P (SELENOP) [ 9 , 10 , 11 ]. These biomarkers correlate over a wide range of Se intakes, since they are not independent from each other and ultimately rely on Se availability and selenoprotein biosynthesis.…”

Section: Introductionmentioning

confidence: 99%

Selenium and Copper as Biomarkers for Pulmonary Arterial Hypertension in Systemic Sclerosis

et al. 2020

Self Cite

View full text Add to dashboard Cite

Circulating selenoprotein P (SELENOP) constitutes an established biomarker of Se status. SELENOP concentrations are reduced in inflammation and severe disease. Recently, elevated SELENOP levels have been suggested as diagnostic marker and therapeutic target in pulmonary arterial hypertension (PAH). We decided to re-evaluate this hypothesis. A group of healthy controls (n = 30) was compared with patients suffering from systemic sclerosis (SSc, n = 66), one third with SSc-related PAH. Serum was analysed for trace elements and protein biomarkers, namely SELENOP, glutathione peroxidase 3 (GPx3) and ceruloplasmin (CP). Compared to controls, patients with SSc-related PAH displayed reduced serum Se (91 ± 2 vs. 68 ± 2 µg/L) and SELENOP concentrations (3.7 ± 0.8 vs. 2.7 ± 0.9 mg/L), along with lower GPx3 activity (278 ± 40 vs. 231 ± 54 U/L). All three biomarkers of Se status were particularly low in patients with skin involvement. Serum Cu was not different between the groups, but patients with SSc-related PAH showed elevated ratios of Cu/Se and CP/SELENOP as compared to controls. Our data indicate that patients with SSc-related PAH are characterized by reduced Se status in combination with elevated CP, in line with other inflammatory diseases. Further analyses are needed to verify the diagnostic value of these TE-related biomarkers in PAH.

show abstract

Selenoprotein P as Biomarker of Selenium Status in Clinical Trials with Therapeutic Dosages of Selenite

Cited by 47 publications

References 44 publications

Selenium and impaired physical function in US and Spanish older adults

Selenium and impaired physical function in US and Spanish older adults

A Comprehensive Review on Selenium and Its Effects on Human Health and Distribution in Middle Eastern Countries

Selenium and Copper as Biomarkers for Pulmonary Arterial Hypertension in Systemic Sclerosis

Contact Info

Product

Resources

About